NO20001020L - Deutererte cyklosporinanaloger og deres anvendelse som immunomodulerende midler - Google Patents

Deutererte cyklosporinanaloger og deres anvendelse som immunomodulerende midler

Info

Publication number: NO20001020L
Authority: NO; Norway
Prior art keywords: cyclosporine; substitution; disclosed; derivatives; cyclosporine derivatives
Prior art date: 1997-10-08

Application number

NO20001020A

Other languages

English (en)

Other versions

NO324042B1 (no

NO20001020D0 (no

Inventor

S Selvaraj Naicker

Randall W Yatscoff

Robert T Foster

Original Assignee

Isotechnika Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-08

Filing date

2000-02-29

Publication date

2000-02-29

2000-02-29 Application filed by Isotechnika Inc filed Critical Isotechnika Inc

2000-02-29 Publication of NO20001020L publication Critical patent/NO20001020L/no

2000-02-29 Publication of NO20001020D0 publication Critical patent/NO20001020D0/no

2007-07-30 Publication of NO324042B1 publication Critical patent/NO324042B1/no

Links

PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title abstract 9
230000002519 immonomodulatory effect Effects 0.000 title 1
238000006467 substitution reaction Methods 0.000 abstract 4
229930105110 Cyclosporin A Natural products 0.000 abstract 3
108010036949 Cyclosporine Proteins 0.000 abstract 3
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 2
229910052805 deuterium Inorganic materials 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
239000000126 substance Substances 0.000 abstract 2
230000001988 toxicity Effects 0.000 abstract 2
231100000419 toxicity Toxicity 0.000 abstract 2
108010036941 Cyclosporins Proteins 0.000 abstract 1
206010062016 Immunosuppression Diseases 0.000 abstract 1
125000003275 alpha amino acid group Chemical class 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
229930182912 cyclosporin Natural products 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
230000000155 isotopic effect Effects 0.000 abstract 1
230000004060 metabolic process Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/807—Hapten conjugated with peptide or protein

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Biochemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Analytical Chemistry (AREA)
Neurology (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Surgery (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

NO20001020A 1997-10-08 2000-02-29 Cyklosporin A derivat, farmasoytisk sammensetning innebefattende samme, anvendelse av samme for fremstilling av medikament og fremgangsmate for fremstilling av samme NO324042B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US6136097P	1997-10-08	1997-10-08
PCT/IB1998/001693 WO1999018120A1 (en)	1997-10-08	1998-10-08	Deuterated cyclosporine analogs and their use as immunomodulating agents

Publications (3)

Publication Number	Publication Date
NO20001020L true NO20001020L (no)	2000-02-29
NO20001020D0 NO20001020D0 (no)	2000-02-29
NO324042B1 NO324042B1 (no)	2007-07-30

Family

ID=22035297

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20001020A NO324042B1 (no)	1997-10-08	2000-02-29	Cyklosporin A derivat, farmasoytisk sammensetning innebefattende samme, anvendelse av samme for fremstilling av medikament og fremgangsmate for fremstilling av samme

Country Status (14)

Country	Link
US (3)	US6613739B1 (no)
EP (1)	EP0991660B8 (no)
JP (6)	JP4261049B2 (no)
KR (1)	KR100585348B1 (no)
AT (2)	ATE314388T1 (no)
AU (1)	AU750245B2 (no)
BR (1)	BR9811716A (no)
CA (1)	CA2298572C (no)
DE (2)	DE69840586D1 (no)
DK (1)	DK0991660T3 (no)
ES (1)	ES2256959T3 (no)
NO (1)	NO324042B1 (no)
NZ (1)	NZ502362A (no)
WO (1)	WO1999018120A1 (no)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030220234A1 (en) *	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
US7144880B2 (en)	1999-04-30	2006-12-05	Regents Of The University Of Michigan	Compositions relating to novel compounds and targets thereof
ATE433752T1 (de)	1999-04-30	2009-07-15	Univ Michigan	Verwendung von benzodiazepinen zur behandlung von autoimmunischen krankheiten, entzündungen, neoplasien, viralen infektionen und atherosklerosis
US20040176358A1 (en) *	1999-04-30	2004-09-09	The Regents Of The University Of Michigan	Compositions and methods relating to novel compounds and targets thereof
US20050113460A1 (en) *	1999-04-30	2005-05-26	The Regents Of The University Of Michigan	Compositions and methods relating to novel compounds and targets thereof
US20030119029A1 (en) *	1999-04-30	2003-06-26	Regents Of The University Of Michigan	Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US20060025388A1 (en)	1999-04-30	2006-02-02	Glick Gary D	Compositions and methods relating to novel compounds and targets thereof
US6784156B2 (en)	2001-03-05	2004-08-31	Enanta Pharmaceuticals, Inc.	Cyclosporins for the treatment of respiratory diseases
US6809077B2 (en)	2001-10-12	2004-10-26	Enanta Pharmaceuticals, Inc.	Cyclosporin analogs for the treatment of autoimmune diseases
US20030087813A1 (en)	2001-10-12	2003-05-08	Or Yat Sun	Cyclosporin analogs for the treatment of lung diseases
EP2116228A1 (en) *	2001-10-19	2009-11-11	Isotechnika Inc.	Novel cyclosporin analog microemulsion preconcentrates
WO2003033526A2 (en) *	2001-10-19	2003-04-24	Isotechnika Inc.	Synthesis of cyclosporin analogs
ES2310604T3 (es) *	2001-10-19	2009-01-16	Isotechnika, Inc.	Mezclas de analogos de ciclosporinas y su uso como agentes inmunomoduladores.
US20040110666A1 (en) *	2002-12-04	2004-06-10	Or Yat Sun	Cyclosporins for the treatment of immune disorders
DE10261807A1 (de) *	2002-12-19	2004-07-01	Turicum Drug Development Ag	Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
US7012065B2 (en)	2003-02-07	2006-03-14	Enanta Pharmaceuticals, Inc.	Cyclosporins for the treatment of immune disorders
JP2006524232A (ja)	2003-03-17	2006-10-26	アルバニーモレキュラーリサーチインコーポレーティッド	新規サイクロスポリン
TW200505946A (en) *	2003-04-08	2005-02-16	Hoffmann La Roche	Process for preparation of cyclosporin a analog
US20040266669A1 (en) *	2003-06-20	2004-12-30	Wu Frank X. H.	Cyclosporin derivatives for the treatment of immune disorders
TW200517114A (en)	2003-10-15	2005-06-01	Combinatorx Inc	Methods and reagents for the treatment of immunoinflammatory disorders
WO2006138673A2 (en) *	2005-06-15	2006-12-28	Cardiome Pharma Corp.	Synthetic processes for the preparation of aminocyclohexyl ether compounds
US7705036B2 (en) *	2004-04-01	2010-04-27	Cardiome Pharma Corp.	Deuterated aminocyclohexyl ether compounds and processes for preparing same
JP4954864B2 (ja) *	2004-04-01	2012-06-20	カーディオムファーマコーポレイション	イオンチャネル調節化合物のプロドラッグおよびその使用
US20050272723A1 (en) *	2004-04-27	2005-12-08	The Regents Of The University Of Michigan	Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20090275099A1 (en) *	2004-04-27	2009-11-05	Regents Of The University Of Michigan	Methods and compositions for treating diseases and conditions associated with mitochondrial function
AU2005326322B2 (en) *	2004-07-01	2009-02-05	Yale University	Targeted and high density drug loaded polymeric materials
US20060014677A1 (en) *	2004-07-19	2006-01-19	Isotechnika International Inc.	Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US7799756B2 (en) *	2004-07-29	2010-09-21	Albany Molecular Research, Inc.	Processes for stereoselective synthesis of trans ISATX247
US20060052369A1 (en) *	2004-09-07	2006-03-09	The Regents Of The University Of Michigan	Compositions and methods relating to novel compounds and targets thereof
EP1804823A4 (en) *	2004-09-29	2010-06-09	Amr Technology Inc	NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS
JP2008514701A (ja) *	2004-09-29	2008-05-08	エーエムアールテクノロジーインコーポレイテッド	シクロスポリンアルキン類似体およびそれらの薬学的使用
US7361636B2 (en)	2004-10-06	2008-04-22	Amr Technology, Inc.	Cyclosporin alkynes and their utility as pharmaceutical agents
JP5159314B2 (ja)	2004-11-18	2013-03-06	カーディオムファーマコーポレイション	アミノシクロヘキシルエーテル化合物の合成方法
CA2592343A1 (en) *	2004-12-17	2006-06-22	Isotechnika Inc.	Metabolites of cyclosporin analogs
JP2008528448A (ja) *	2005-01-03	2008-07-31	ザリージェンツオブザユニバーシティオブミシガン	新規化合物に関連する組成物および方法、ならびにその標的
EP1875250B1 (en) *	2005-04-06	2010-01-27	Abbott Laboratories	Methods to measure immunosuppressive tacrolimus, sirolimus, and cyclosporin a complexes in a blood sample
WO2007053193A2 (en)	2005-06-01	2007-05-10	The Regents Of The University Of Michigan	Unsolvated benzodiazepine compositions and methods
US7598273B2 (en) *	2005-10-06	2009-10-06	Auspex Pharmaceuticals, Inc	Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
US20070105844A1 (en) *	2005-10-26	2007-05-10	Regents Of The University Of Michigan	Therapeutic compositions and methods
NZ568254A (en)	2005-11-01	2011-06-30	Univ Michigan	1,4-Benzodiazepine-2,5-diones for regulating cell death and treating autoimmune diseases
ZA200804550B (en)	2005-11-09	2009-08-26	Combinatorx Inc	Methods, compositions, and kits for the treatment of medical conditions
PT1954669E (pt)	2005-12-01	2015-10-23	Auspex Pharmaceuticals Inc	Feniletilaminas substituídas com actividade serotoninérgica e/ou norepinefrinérgica
GB0604647D0 (en) *	2006-03-08	2006-04-19	Shchepinov Mikhail	Stabilized food supplements and their derivatives
US7696166B2 (en) *	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) *	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7759338B2 (en) *	2006-04-27	2010-07-20	The Regents Of The University Of Michigan	Soluble 1,4 benzodiazepine compounds and stable salts thereof
US8155649B2 (en) *	2006-05-12	2012-04-10	Shared Spectrum Company	Method and system for classifying communication signals in a dynamic spectrum access system
EP2418206A3 (en)	2006-06-09	2012-06-27	The Regents of the University of Michigan	Benzodiazepine derivatives useful in the treatment of autoimmune disorders
US10265407B2 (en)	2007-02-15	2019-04-23	Yale University	Modular nanodevices for smart adaptable vaccines
WO2008109347A2 (en) *	2007-03-02	2008-09-12	Yale University	Methods for ex vivo administration of drugs to grafts using polymeric nanoparticles
CA2680017C (en)	2007-03-09	2013-11-12	The Regents Of The University Of Michigan	Compositions and methods relating to novel compounds and targets thereof
ES2693948T3 (es)	2007-03-15	2018-12-14	Auspex Pharmaceuticals, Inc.	Fenetilamina sustituida con actividad serotoninérgica y/o norepinefrinérgica
WO2009018424A2 (en) *	2007-08-01	2009-02-05	Emory University	Methods for determination of protein phosphatase activity, and uses in predicting therapeutic outcomes
CN101855203B (zh)	2007-09-14	2014-03-19	密执安州立大学董事会	F1f0-atp合成酶抑制剂以及相关的方法
UA99839C2 (ru)	2007-11-06	2012-10-10	Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган	Бензодиазепиноновые соединения, применяемые при лечении кожных состояний
CA2715036A1 (en)	2008-03-14	2009-09-17	Retrotope, Inc.	Therapies for cancer using isotopically substituted lysine
WO2010009243A1 (en) *	2008-07-15	2010-01-21	Theracos, Inc.	Deuterated benzylbenzene derivatives and methods of use
BRPI0911709A2 (pt) *	2008-07-30	2017-06-20	Isotechnika Labs Inc	composto, processo para a produção de um composto, composição farmacêutica e método de tratar uma doença mediada a ciclofilina em um mamífero
US8541419B2 (en) *	2008-09-02	2013-09-24	Actimis Pharmaceuticals, Inc.	Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists
MX2011002033A (es) *	2008-09-03	2011-05-02	Teva Pharma	2-oxo-1,2-dihidro-quinolinas moduladoras de la funcion inmune.
EP2352724B1 (en)	2008-09-11	2015-04-22	The Regents of the University of Michigan	Aryl guanidine f1f0-atpase inhibitors and their medical use
WO2010048332A2 (en) *	2008-10-22	2010-04-29	Acucela, Inc.	Compounds for treating ophthalmic diseases and disorders
SG173180A1 (en)	2009-01-30	2011-09-29	Enanta Pharm Inc	Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en)	2009-02-19	2013-07-09	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US8604023B2 (en)	2009-04-17	2013-12-10	The Regents Of The University Of Michigan	1,4-benzodiazepinone compounds and their use in treating cancer
US8349312B2 (en)	2009-07-09	2013-01-08	Enanta Pharmaceuticals, Inc.	Proline substituted cyclosporin analogues
US8367053B2 (en)	2009-07-09	2013-02-05	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US8685917B2 (en)	2009-07-09	2014-04-01	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
WO2011035124A1 (en)	2009-09-18	2011-03-24	The Regents Of The University Of Michigan	Benzodiazepinone compounds and methods of treatment using same
AU2010313249B2 (en)	2009-10-30	2016-05-19	Biojiva Llc	Alleviating oxidative stress disorders with PUFA derivatives
JP5856064B2 (ja)	2009-11-17	2016-02-09	ザリージェンツオブザユニバーシティオブミシガン	治療特性を有する１，４−ベンゾジアゼピン−２，５−ジオンおよび関連化合物
EP2501387B1 (en)	2009-11-17	2016-07-27	The Regents Of The University Of Michigan	1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
US20110130711A1 (en) *	2009-11-19	2011-06-02	Follica, Inc.	Hair growth treatment
UY33226A (es) *	2010-02-19	2011-09-30	Novartis Ag	Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
US8623814B2 (en)	2010-02-23	2014-01-07	Enanta Pharmaceuticals, Inc.	Antiviral agents
JP6144627B2 (ja)	2010-12-15	2017-06-07	コントラヴィアファーマシューティカルズ、インク．	アミノ酸１および３で修飾されたシクロスポリン類似体分子
WO2012145427A1 (en)	2011-04-18	2012-10-26	The Trustees Of Columbia University In The City Of New York	Methods to treat cancer using cyclosporine and cyclosporine derivatives
KR102110200B1 (ko)	2011-04-26	2020-05-13	레트로토프 인코포레이티드	산화성 망막 질환
JP6145087B2 (ja)	2011-04-26	2017-06-07	レトロトップ、インコーポレイテッドＲｅｔｒｏｔｏｐｅ，Ｉｎｃ．	Ｐｕｆａ酸化関与障害
KR102020579B1 (ko)	2011-04-26	2019-09-10	레트로토프 인코포레이티드	에너지 프로세싱 손상 장애 및 미토콘드리아 결함
KR102020611B1 (ko)	2011-04-26	2019-09-10	레트로토프 인코포레이티드	Ｐｕｆａ와 관련된 신경퇴행성 질환 및 근육 질환
DE102011111991A1 (de)	2011-08-30	2013-02-28	Lead Discovery Center Gmbh	Neue Cyclosporin-Derivate
EP2780448B1 (en)	2011-11-18	2019-09-11	Codexis, Inc.	Biocatalysts for the preparation of hydroxy substituted carbamates
WO2013163176A1 (en)	2012-04-23	2013-10-31	Allertein Therapeutics, Llc	Nanoparticles for treatment of allergy
US8906853B2 (en)	2012-11-28	2014-12-09	Enanta Pharmaceuticals, Inc.	[N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
KR102233251B1 (ko)	2013-04-03	2021-03-26	엔-폴드 엘엘씨	신규 나노입자 조성물
SG11201601274QA (en)	2013-08-26	2016-03-30	Enanta Pharm Inc	Cyclosporin analogues for preventing or treating hepatitis c
CA2935167C (en)	2014-01-16	2022-02-22	Musc Foundation For Research Development	Targeted nanocarriers for the administration of immunosuppressive agents
WO2016073480A1 (en)	2014-11-03	2016-05-12	Enanta Pharmaceuticals, Inc.	Novel cyclosporin analogues for preventing or treating hepatitis c infection
MX2018001507A (es)	2015-08-03	2018-09-18	Enb Therapeutics Llc	Composiciones y metodos para tratar cánceres asociados con la activacion del etbr.
CN108698987B (zh)	2015-11-23	2021-07-13	乐巢拓普有限公司	1,4-二烯体系的位点特异性同位素标记
WO2018106928A1 (en)	2016-12-08	2018-06-14	Contravir Pharmaceuticals, Inc.	Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
CN111886010A (zh)	2018-01-12	2020-11-03	Enb治疗公司	用于治疗与etbr激活相关的癌症的氘化化合物、组合物和方法
WO2020082061A1 (en)	2018-10-19	2020-04-23	Teva Pharmaceuticals International Gmbh	Solid state forms of voclosporin
KR20260018193A (ko)	2020-02-21	2026-02-06	레트로토프 인코포레이티드	고도불포화 지방산 및 이의 유도체의 동위원소 변형을 위한 공정
IL296586B1 (en) *	2020-03-26	2026-04-01	Farsight Medical Tech Shanghai Co Ltd	Cyclophilin inhibitors and their uses
US12109194B2 (en)	2021-02-05	2024-10-08	Biojiva Llc	Synergistic combination therapy for treating ALS
EP4201952A1 (en)	2021-12-21	2023-06-28	Curia Spain, S.A.U.	Process for the controlled synthesis of voclosporin
IT202300001116A1 (it) *	2023-01-25	2024-07-25	Indena Spa	Processo per la preparazione di un intermedio utile per la sintesi di voclosporina
WO2025119925A1 (en)	2023-12-05	2025-06-12	Medichem, S.A.	Process for preparing voclosporin

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH614931A5 (no)	1975-11-04	1979-12-28	Sandoz Ag
US4210581A (en)	1975-11-04	1980-07-01	Sandoz Ltd.	Organic compounds
US4117118A (en)	1976-04-09	1978-09-26	Sandoz Ltd.	Organic compounds
DE2819094A1 (de)	1977-05-10	1978-11-23	Sandoz Ag	Cyclosporin-derivate, ihre verwendung und herstellung
SE448386B (sv)	1978-10-18	1987-02-16	Sandoz Ag	Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
US4201771A (en)	1979-03-12	1980-05-06	Merck & Co., Inc.	Antibiotic A43F
EP0034567B1 (en)	1980-02-14	1984-11-07	Sandoz Ag	A method for the total synthesis of cyclosporins and novel cyclosporins
US4396542A (en)	1980-02-14	1983-08-02	Sandoz Ltd.	Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
FR2487198A1 (fr)	1980-07-28	1982-01-29	Berri Balzac Sa	Nouvelle substance immuno-suppressive, son procede d'isolement et son application en therapeutique
DE3260468D1 (en)	1981-01-09	1984-09-06	Sandoz Ag	Novel cyclosporins
CH667274A5 (de)	1984-03-23	1988-09-30	Sandoz Ag	Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
US4727018A (en)	1984-05-18	1988-02-23	Eichner Ronald D	Immunoregulation of transplantable tissue
US5639724A (en)	1984-07-24	1997-06-17	Sandoz Ltd.	Cyclosporin galenic forms
GB8422253D0 (en)	1984-09-04	1984-10-10	Sandoz Ltd	Organic compounds
EP0194972B1 (en)	1985-03-11	1992-07-29	Sandoz Ag	Novel cyclosporins
US4765980A (en)	1986-04-28	1988-08-23	International Minerals & Chemical Corp.	Stabilized porcine growth hormone
US4764503A (en)	1986-11-19	1988-08-16	Sandoz Ltd.	Novel cyclosporins
NL194638C (nl)	1986-12-19	2002-10-04	Novartis Ag	Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat.
US5427960A (en)	1987-03-27	1995-06-27	Abbott Laboratories	Fluorescence polarization assay for cyclosporin A and metabolites and related immunogens and antibodies
US5239057A (en)	1987-03-27	1993-08-24	Abbott Laboratories	Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
EP0283801A3 (en) *	1987-03-27	1990-05-30	Abbott Laboratories	Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
US4798823A (en)	1987-06-03	1989-01-17	Merck & Co., Inc.	New cyclosporin analogs with modified "C-9 amino acids"
US4885276A (en)	1987-06-03	1989-12-05	Merck & Co., Inc.	Cyclosporin analogs with modified "C-9 amino acids"
JP2577049B2 (ja)	1987-06-04	1997-01-29	三共株式会社	シクロスポリン製剤
ES2059558T3 (es) *	1987-06-17	1994-11-16	Sandoz Ag	Ciclosporins y su uso como productos farmaceuticos.
ATE110784T1 (de)	1987-06-19	1994-09-15	Sandoz Ag	Zyklische peptolide.
DE3888357T2 (de)	1987-06-22	1994-09-15	Merck & Co Inc	Cyclosporin-Derivate, die eine modifizierte Aminosäure auf Stellung 8 tragen.
GB8717299D0 (en)	1987-07-22	1987-08-26	Nat Res Dev	Peptides
GB8717300D0 (en)	1987-07-22	1987-08-26	Nat Res Dev	Cyclosporins
US5227467A (en)	1987-08-03	1993-07-13	Merck & Co., Inc.	Immunosuppressive fluorinated cyclosporin analogs
US4963362A (en)	1987-08-07	1990-10-16	Regents Of The University Of Minnesota	Freeze-dried liposome mixture containing cyclosporin
KR920003601B1 (ko)	1987-09-03	1992-05-04	유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드	점안 싸이클로스포린(cyclosporin)의 조성물
US4839342A (en)	1987-09-03	1989-06-13	University Of Georgia Research Foundation, Inc.	Method of increasing tear production by topical administration of cyclosporin
US5089390A (en)	1987-09-04	1992-02-18	Syntex (U.S.A.) Inc.	2-methyl-4-hexene- and 2-methyl-4-heptene-1,2-diol derivatives
US4914188A (en)	1987-11-16	1990-04-03	Merck & Co., Inc.	Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
US5236899A (en)	1987-11-16	1993-08-17	Merck & Co., Inc.	6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
US5013719A (en)	1988-05-13	1991-05-07	Merrell Dow Pharmaceuticals Inc.	Method of effecting immunosuppression
KR0148748B1 (ko)	1988-09-16	1998-08-17	장 크라메르, 한스 루돌프 하우스	사이클로스포린을 함유하는 약학조성물
US5342625A (en)	1988-09-16	1994-08-30	Sandoz Ltd.	Pharmaceutical compositions comprising cyclosporins
JPH04502328A (ja)	1988-12-05	1992-04-23	ザ・トラステイーズ・オブ・コロンビア・ユニヴアーシテイ・イン・ザ・シテイ・オブ・ニユー・ヨーク	シクロスポリンａの新規誘導体、それに対する抗体及びその使用
US4996193A (en)	1989-03-03	1991-02-26	The Regents Of The University Of California	Combined topical and systemic method of administration of cyclosporine
US5540931A (en)	1989-03-03	1996-07-30	Charles W. Hewitt	Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5284826A (en)	1989-07-24	1994-02-08	Sandoz Ltd.	0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
US5122511A (en)	1990-02-27	1992-06-16	Merck & Co., Inc.	Immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5214130A (en)	1990-02-27	1993-05-25	Merck & Co., Inc.	Synthesis of novel immunosuppressive cyclosporin analogs with modified amino acids at position-8
DE69116034T2 (de)	1990-08-15	1996-06-20	Abbott Lab	Immunotestreagenzien und Verfahren zur Bestimmung von Cyclosporin
ATE148469T1 (de)	1990-11-02	1997-02-15	Sandoz Ag	Zyklosporine
US5115859A (en)	1990-12-21	1992-05-26	United Technologies Corporation	Regenerable non-venting cooler for protective suit
ES2078374T3 (es)	1991-04-06	1995-12-16	Dresden Arzneimittel	Procedimiento para la produccion por fermentacion y aislamiento de ciclosporina a, y nuevas cepas formadoras de ciclosporina.
GB9204466D0 (en) *	1992-03-02	1992-04-15	Sandoz Ltd	Improvements in or relating to organic compounds
HU213553B (en)	1992-05-25	1997-07-28	Biogal Gyogyszergyar	Process for isolating of cyclosporin-a
FI92334C (fi)	1992-12-30	1994-10-25	Leiras Oy	Menetelmä syklosporiinien tuottamiseksi ja menetelmässä käytettävä uusi Tolypocladium-kanta
CA2161149A1 (en)	1993-05-04	1994-11-10	James M. Balkovec	Cyclohexapeptidyl aminoalkyl ethers
CN1087725C (zh) *	1994-03-25	2002-07-17	同位素技术有限公司	用氘代方法增强药物效果
US5639852A (en)	1994-09-01	1997-06-17	Wisconsin Alumni Research Foundation	Immunostimulatory agents
US5624902A (en)	1995-06-07	1997-04-29	Torrey Pines Institute For Molecular Studies	Peptide inhibitors of calmodulin
US5616595A (en)	1995-06-07	1997-04-01	Abbott Laboratories	Process for recovering water insoluble compounds from a fermentation broth
US5747330A (en)	1996-06-05	1998-05-05	Poli Industria Chimica	Antibiotic producing microbe
US5709797A (en)	1996-06-05	1998-01-20	Poli Industria Chimica S.P.A.	Method of isolating cyclosporins

1998
- 1998-10-08 AU AU94542/98A patent/AU750245B2/en not_active Expired
- 1998-10-08 CA CA002298572A patent/CA2298572C/en not_active Expired - Lifetime
- 1998-10-08 NZ NZ502362A patent/NZ502362A/en not_active IP Right Cessation
- 1998-10-08 ES ES98947718T patent/ES2256959T3/es not_active Expired - Lifetime
- 1998-10-08 AT AT98947718T patent/ATE314388T1/de active
- 1998-10-08 BR BR9811716-5A patent/BR9811716A/pt not_active Application Discontinuation
- 1998-10-08 DE DE69840586T patent/DE69840586D1/de not_active Expired - Fee Related
- 1998-10-08 DK DK98947718T patent/DK0991660T3/da active
- 1998-10-08 EP EP98947718A patent/EP0991660B8/en not_active Expired - Lifetime
- 1998-10-08 WO PCT/IB1998/001693 patent/WO1999018120A1/en not_active Ceased
- 1998-10-08 DE DE69832984T patent/DE69832984T2/de not_active Expired - Lifetime
- 1998-10-08 JP JP2000514928A patent/JP4261049B2/ja not_active Expired - Lifetime
- 1998-10-08 AT AT05024216T patent/ATE423130T1/de not_active IP Right Cessation
- 1998-10-08 KR KR1020007003743A patent/KR100585348B1/ko not_active Expired - Fee Related
2000
- 2000-02-29 NO NO20001020A patent/NO324042B1/no not_active IP Right Cessation
- 2000-08-07 US US09/634,945 patent/US6613739B1/en not_active Expired - Lifetime
- 2000-08-14 US US09/639,708 patent/US6605593B1/en not_active Expired - Lifetime
2001
- 2001-11-07 US US09/985,997 patent/US20020132763A1/en not_active Abandoned
2003
- 2003-10-17 JP JP2003358524A patent/JP2004143168A/ja not_active Withdrawn
2005
- 2005-08-11 JP JP2005233674A patent/JP2005343904A/ja not_active Withdrawn
2007
- 2007-01-26 JP JP2007017196A patent/JP2007119489A/ja not_active Withdrawn
2008
- 2008-05-27 JP JP2008138789A patent/JP2008222724A/ja not_active Withdrawn
- 2008-05-27 JP JP2008138790A patent/JP2008222725A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP2008222725A (ja)	2008-09-25
KR20010030978A (ko)	2001-04-16
ATE423130T1 (de)	2009-03-15
BR9811716A (pt)	2000-07-18
JP2007119489A (ja)	2007-05-17
JP2001519355A (ja)	2001-10-23
AU9454298A (en)	1999-04-27
EP0991660B1 (en)	2005-12-28
ES2256959T3 (es)	2006-07-16
JP4261049B2 (ja)	2009-04-30
EP0991660A1 (en)	2000-04-12
US6613739B1 (en)	2003-09-02
JP2005343904A (ja)	2005-12-15
ATE314388T1 (de)	2006-01-15
DE69840586D1 (de)	2009-04-02
CA2298572A1 (en)	1999-04-15
US6605593B1 (en)	2003-08-12
EP0991660B8 (en)	2006-04-05
JP2008222724A (ja)	2008-09-25
NO324042B1 (no)	2007-07-30
US20020132763A1 (en)	2002-09-19
DE69832984T2 (de)	2006-09-21
DE69832984D1 (de)	2006-02-02
NO20001020D0 (no)	2000-02-29
HK1026432A1 (en)	2000-12-15
DK0991660T3 (da)	2006-02-13
KR100585348B1 (ko)	2006-06-01
JP2004143168A (ja)	2004-05-20
WO1999018120A1 (en)	1999-04-15
NZ502362A (en)	2001-05-25
AU750245B2 (en)	2002-07-11
CA2298572C (en)	2002-04-09

Legal Events

Date	Code	Title	Description
2011-09-26	CREP	Change of representative	Representative=s name: CURO AS, INDUSTRIVEIEN 53, 7080
2015-06-29	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: AURINIA PHARMACEUTICALS INC, CA
2015-06-29	CREP	Change of representative	Representative=s name: ACAPO AS, POSTBOKS 1880 NORDNES, 5817 BERGEN, NORG
2018-11-12	MK1K	Patent expired

Publication	Publication Date	Title
NO20001020D0 (no)	2000-02-29	Deutererte cyklosporinanaloger og deres anvendelse som immunomodulerende midler
Kruger et al.	1999	Electron capture dissociation of multiply charged peptide cations
Kenny et al.	1992	Fragmentation studies of peptides: the formation of y ions
AU9315398A (en)	1999-03-29	Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
HUP0002381A1 (hu)	2000-10-28	Apolipoprotein A-1 agonista hatású peptidszármazékok, ezek lipidekkel alkotott komplexei, valamint ezeket tartalmazó gyógyászati készítmények
WO2003031464A3 (en)	2006-03-02	Remodeling and glycoconjugation of peptides
DE69912952D1 (en)	2003-12-24	Cyclosporine
WO2004099231A3 (en)	2006-03-16	Glycopegylation methods and proteins/peptides produced by the methods
NO961075L (no)	1996-03-15	Krystallinsk, vannfritt mykofenolatmofetil og intravenöst preparat derav
ATE331037T1 (de)	2006-07-15	Isoliertes frpb nukleinsäuremolekül und entsprechende impfstoff
HUT64567A (en)	1994-01-28	Method for producing new cyclosporines and preparations containing said compounds as active agent
EP0174279A3 (en)	1989-01-25	Improvements in relation to cyclosporin therapy
NO995481L (no)	1999-11-09	Glykokonjugater av 20 (S)-camptothecin
NO302072B1 (no)	1998-01-19	Azabicyklo-arylacetylen- og -arylenyn-oksimer som cholinerge midler og preparater inneholdende slike
BR9407693A (pt)	1997-02-04	Sequência nucleotídica vetor composiçao farmacêutica utilizaçao do vetor e de um composto
WO2000058456A3 (en)	2001-02-15	Compositions and methods for modifying toxic effects of proteinacious compounds
WO2004091475A3 (en)	2007-04-19	Gaucher disease drugs and methods of identifying same
AU6415994A (en)	1994-10-24	Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
WO2002024213A3 (en)	2002-06-13	Improved protocol for paracentesis
IT1319674B1 (it)	2003-10-23	Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
Inoue et al.	2000	Heterogeneous post‐translational modification of Actinobacillus actinomycetemcomitans fimbrillin
CA2511888A1 (en)	1999-04-15	Deuterated cyclosporin analogs and their use as immunomodulating agents
CA2372639A1 (en)	1999-04-15	Deuterated cyclosporine analogs and their use as immunomodulating agents
EA200000736A1 (ru)	2001-04-23	Фармацевтические композиции
PL338294A1 (en)	2000-10-23	Derivatives of streptogramins, method of obtaining them and compositions containing such derivatives